Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer

NCT01038804 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT01038804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01038804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2009
Completion date
June 30, 2013
Enrollment
101 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer